Status:
COMPLETED
Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Membranous Nephropathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Membranous Nephropathy (MN) is an auto-immune kidney disease and a common cause of nephrotic syndrome. About 30% of MN patients progress to end-stage kidney disease (ESKD) while 30% undergo spontaneou...
Detailed Description
Membranous Nephropathy (MN) is an auto-immune kidney disease and a common cause of nephrotic syndrome. About 30% of MN patients progress to end-stage kidney disease (ESKD) while 30% undergo spontaneou...
Eligibility Criteria
Inclusion
- Adult patients
- Patients with MN stade I-II confirmed by kidney biopsy
- Patients with MDRD\>30 ml/mn/1.73m2
- Patients with anti-PLA2R1 antibodies
- Effective Contraception for women of childbearing age
Exclusion
- Patients minors
- Patients refusing to participate in the study
- Patients with secondary MN (systemic Lupus, hepatitis B virus, hepatitis C virus or cancer)
- Pregnant women: a urine pregnancy test will be performed for women of childbearing age. The results will be communicated to the patient by a doctor of his choice.
- Persons deprived of liberty (administrative or judicial)
- Persons under guardianship
- People may not understand the research
- Persons under guardianship, under judicial protection
Key Trial Info
Start Date :
July 17 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 4 2020
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT02199145
Start Date
July 17 2015
End Date
June 4 2020
Last Update
November 18 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Besançon
Besançon, France
2
AP-HM
Marseille, France, 13354
3
Nephrology Department, Nice University Hospital
Nice, France, 06003